A large observational study suggests long-acting injectable antipsychotics are associated with better outcomes than oral antipsychotics in people with schizophrenia.

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia – JAMA Network Open

Invited Commentary: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open

Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial – JAMA Psychiatry

Commentary on Twitter

This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0

— JAMA Network Open (@JAMANetworkOpen) July 28, 2022

Stay Updated in Your Specialty